HAWKINS INC
For the period ended Dec 31, 2023. Filed Jan 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Jan 31, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Financial Statements
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
Note 1 – Summary of Significant Accounting Policies
Basis of Presentation. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions for Form 10-Q and, accordingly, do not include all information and footnotes required by generally accepted accounting principles for complete financial statements. These financial statements should be read in conjunction with the consolidated financial statements and footnotes included in our Annual Report on Form 10-K for the fiscal year ended April 2, 2023, previously filed with the Securities and Exchange Commission (“SEC”). In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly our financial position and the results of our operations and cash flows for the periods presented. All adjustments made to the interim condensed consolidated financial statements were of a normal recurring nature. All significant intercompany accounts and transactions have been eliminated in consolidation. The results of operations for the nine months ended December 31, 2023 are not necessarily indicative of the results that may be expected for the full year.
References to fiscal 2023 refer to the fiscal year ended April 2, 2023 and references to fiscal 2024 refer to the fiscal year ending March 31, 2024.
Use of Estimates. The preparation of condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, particularly receivables, inventories, property, plant and equipment, right-of-use assets, goodwill, intangibles, accrued expenses, short-term and long-term lease liability, income taxes and related accounts and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounting Policies. The accounting policies we follow are set forth in Note 1 – Nature of Business and Significant Accounting Policies to our consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended April 2, 2023, previously filed with the SEC. There has been no significant change in our accounting policies since the end of fiscal 2023.
Note 2 —Acquisitions and Asset Sales
Acquisition of The Miami Products & Chemical Company: On October 31, 2023, we acquired substantially all the assets of The Miami Products & Chemical Company ("Miami Products") for $15.5 million under the terms of a purchase agreement with Miami Products and its shareholders. Miami Products is a bleach manufacturer and distributor serving customers primarily throughout Ohio and the surrounding region. The results of operations since the acquisition date and the assets are included in our Water Treatment segment. Costs associated with this transaction were not material and were expensed as incurred.
The acquisition has been accounted for under the acquisition method of accounting, under which the total purchase price is allocated to the net tangible and intangible assets and liabilities of Miami Products acquired in connection with the acquisition based on their estimated fair values. We estimated the fair values of the assets acquired and liabilities assumed using a discounted cash flow analysis (income approach). Of the $15.5 million purchase price, $8.2 million was allocated to customer lists, to be amortized over 11 years, and $0.8 million was allocated to trade names, to be amortized over 10 years. The remaining amount was allocated to net working capital and property, plant and equipment, with the residual amount of $3.1 million allocated to goodwill. The goodwill recognized as a result of this acquisition is primarily attributable to strategic and synergistic benefits, as well as the assembled workforce. Such goodwill is expected to be deductible for tax purposes. The purchase price allocation is preliminary and subject to adjustment within the first 12 months following the acquisition.
Acquisition of Water Solutions Unlimited, Inc.: On October 27, 2023, we acquired substantially all the assets of Water Solutions Unlimited, Inc. ("Water Solutions") under the terms of a purchase agreement with Water Solutions and its shareholders. We paid $60 million at closing and may be obligated to pay an additional amount based on achieving a certain earnings target three years after the acquisition. Water Solutions is a manufacturer and distributor of water treatment chemicals serving customers primarily throughout Indiana, Illinois and Michigan. The results of operations since the acquisition date and the assets are included in our Water Treatment segment. Costs associated with this transaction were not material and were expensed as incurred.
The acquisition has been accounted for under the acquisition method of accounting, under which the total purchase price is allocated to the net tangible and intangible assets and liabilities of Water Solutions acquired in connection with the acquisition based on their estimated fair values. We estimated the fair values of the assets acquired and liabilities assumed using a discounted cash flow analysis (income approach). The total purchase price was estimated to be $70.7 million, including the estimated potential earnout to be paid of $10.7 million. Of the $70.7 million purchase price, $32.0 million was allocated to customer lists, to be amortized over 13 years, $6.4 million was allocated to trade names, to be amortized over 10 years, and $0.2 million was allocated to non-compete agreements, to be amortized over five years. The remaining amount was allocated to net working capital and property, plant and equipment, with the residual amount of $21.0 million allocated to goodwill. The goodwill recognized as a result of this acquisition is primarily attributable to strategic and synergistic benefits, as well as the assembled workforce. Such goodwill is expected to be deductible for tax purposes. The purchase price allocation is preliminary and subject to adjustment within the first 12 months following the acquisition.
Acquisition of EcoTech Enterprises, Inc.: On July 14, 2023, we acquired substantially all the assets of EcoTech Enterprises, Inc. ("EcoTech") for $3.4 million, under the terms of a purchase agreement with EcoTech and its shareholders. EcoTech was a water treatment chemical distribution company operating primarily in Arkansas. The $3.4 million purchase price was allocated primarily to customer lists, to be amortized over 10 years, property, plant and equipment, and net working capital. The results of operations since the acquisition date and the assets are included in our Water Treatment segment. Costs associated with this transaction were not material and were expensed as incurred.
Sale of bleach packaging assets: In the fourth quarter of fiscal 2023, we sold certain assets in our Industrial segment related to our consumer bleach packaging business for $7 million. These assets were not core to our Industrial segment operations, where we tend to focus our manufacturing operations on bulk products. The assets sold included plant equipment, inventory and intangible assets, all related to the packaging of bleach. We realized a gain of $3 million on this sale, which has been recorded within selling, general and administrative expenses.
Note 3 -Revenue
Our revenue arrangements generally consist of a single performance obligation to transfer promised goods or services. We disaggregate revenues from contracts with customers by operating segments as well as types of products sold. Reporting by operating segment is pertinent to understanding our revenues, as it aligns to how we review the financial performance of our operations. Types of products sold within each operating segment help us to further evaluate the financial performance of our segments. The following tables disaggregate external customer net sales by major revenue stream for the nine months ended December 31, 2023 and January 1, 2023:
| Three months ended December 31, 2023 | ||||
|---|---|---|---|---|
| (In thousands) | Industrial | Water Treatment | Health and Nutrition | Total |
| Manufactured, blended or repackaged products (1) | $78,313 | $73,406 | $7,857 | $159,576 |
| Distributed specialty products (2) | — | — | 25,678 | 25,678 |
| Bulk products (3) | 12,921 | 7,629 | — | 20,550 |
| Other | 1,756 | 984 | (48) | 2,692 |
| Total external customer sales | $92,990 | $82,019 | $33,487 | $208,496 |
| Three months ended January 1, 2023 | ||||
| (In thousands) | Industrial | Water Treatment | Health and Nutrition | Total |
| Manufactured, blended or repackaged products (1) | $91,658 | $60,583 | $11,935 | $164,176 |
| Distributed specialty products (2) | — | — | 23,833 | 23,833 |
| Bulk products (3) | 20,364 | 6,649 | — | 27,013 |
| Other | 2,414 | 1,317 | 465 | 4,196 |
| Total external customer sales | $114,436 | $68,549 | $36,233 | $219,218 |
| Nine months ended December 31, 2023 | ||||
| (In thousands) | Industrial | Water Treatment | Health and Nutrition | Total |
| Manufactured, blended or repackaged products (1) | $264,878 | $249,155 | $28,956 | $542,989 |
| Distributed specialty products (2) | — | — | 77,945 | 77,945 |
| Bulk products (3) | 41,280 | 23,710 | — | 64,990 |
| Other | 6,240 | 3,730 | 248 | 10,218 |
| Total external customer sales | $312,398 | $276,595 | $107,149 | $696,142 |
| Nine months ended January 1, 2023 | ||||
| (In thousands) | Industrial | Water Treatment | Health and Nutrition | Total |
| Manufactured, blended or repackaged products (1) | $286,818 | $208,112 | $35,632 | $530,562 |
| Distributed specialty products (2) | — | — | 83,599 | 83,599 |
| Bulk products (3) | 58,951 | 21,159 | — | 80,110 |
| Other | 7,316 | 4,256 | 1,110 | 12,682 |
| Total external customer sales | $353,085 | $233,527 | $120,341 | $706,953 |
(1)For our Industrial and Water Treatment segments, this line includes our non-bulk specialty products that we either manufacture, blend, repackage, resell in their original form, or direct ship to our customers in smaller quantities, and services we provide for our customers. For our Health and Nutrition segment, this line includes products manufactured, processed or repackaged in our facility and/or with our equipment.
(2)This line includes non-manufactured distributed specialty products in our Health and Nutrition segment, which may be sold out of one of our facilities or direct shipped to our customers.
(3)This line includes bulk products in our Industrial and Water Treatment segments that we do not modify in any way, but receive, store, and ship from our facilities, or direct ship to our customers in large quantities.
Note 4 –Earnings per Share
Basic earnings per share (“EPS”) is computed by dividing net earnings by the weighted-average number of common shares outstanding. Diluted EPS includes the dilutive impact of incremental shares assumed to be issued as performance units and restricted stock.
Basic and diluted EPS were calculated using the following:
| Three Months Ended | Nine Months Ended | |||
|---|---|---|---|---|
| December 31, 2023 | January 01, 2023 | December 31, 2023 | January 01, 2023 | |
| Weighted-average common shares outstanding—basic | 20,781,632 | 20,818,347 | 20,864,349 | 20,847,285 |
| Dilutive impact of performance units and restricted stock | 125,689 | 155,917 | 139,728 | 157,564 |
| Weighted-average common shares outstanding—diluted | 20,907,321 | 20,974,264 | 21,004,077 | 21,004,849 |
For each of the periods presented, there wereno shares excluded from the calculation of weighted-average common shares for diluted EPS.
Note 5 –Fair Value Measurements
Our financial assets and liabilities are measured at fair value at the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The carrying value of cash equivalents, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these instruments. Because of the variable-rate nature of our debt under our credit facility, our debt also approximates fair value.
Assets and Liabilities Measured at Fair Value on a Recurring Basis. The fair value hierarchy requires the use of observable market data when available. In instances where inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Our assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.
Our financial assets that are measured at fair value on a recurring basis are an interest rate swap and assets held in a deferred compensation retirement plan. Both of these assets are classified as long-term assets on our balance sheet, with the portion of the deferred compensation retirement plan assets expected to be paid within twelve months classified as current assets. The fair value of the interest rate swap is determined by the respective counterparties based on interest rate changes. Interest rate swaps are valued based on observable interest rate yield curves for similar instruments. The deferred compensation plan assets relate to contributions made to a non-qualified compensation plan on behalf of certain employees who are classified as “highly compensated employees” as determined by IRS guidelines. The assets are part of a rabbi trust and the funds are held in mutual funds. The fair value of the deferred compensation is based on the quoted market prices for the mutual funds at the end of the period.
The following tables summarize the balances of assets and liabilities measured at fair value on a recurring basis as of December 31, 2023 and April 2, 2023.
| (In thousands) · December 31, 2023 · April 2, 2023 | |||
|---|---|---|---|
| Assets | |||
| Deferred compensation plan assets | Level 1 | $9,803 | $7,659 |
| Interest rate swap | Level 2 | $3,694 | $4,028 |
Note 6 –Inventories
Inventories at December 31, 2023 and April 2, 2023 consisted of the following:
| December 31,2023 | April 2,2023 | |
|---|---|---|
| (In thousands) | ||
| Inventory (FIFO basis) | $102,657 | $128,589 |
| LIFO reserve | (33,852) | (39,812) |
| Net inventory | $68,805 | $88,777 |
The first in, first out (“FIFO”) value of inventories accounted for under the last in, first out (“LIFO”) method was $78.7 million at December 31, 2023 and $101.4 million at April 2, 2023. The remainder of the inventory was valued and accounted for under the FIFO method.
Note 7 –Goodwill and Intangible Assets
The carrying amount of goodwill was $101.5 million as of December 31, 2023 and $77.4 million as of April 2, 2023, of which $44.9 million was related to our Health and Nutrition segment, $50.1 million was related to our Water Treatment segment, and $6.5 million was related to our Industrial segment. The increase in goodwill during the nine months ended December 31, 2023 represents goodwill recorded in connection with the acquisitions of the assets of Water Solutions and Miami Products as discussed in Note 2.
A summary of our intangible assets as of December 31, 2023 and April 2, 2023 is as follows:
| December 31, 2023 · April 2, 2023 | ||||||
|---|---|---|---|---|---|---|
| (In thousands) | GrossAmount | AccumulatedAmortization | Net | Gross Amount | AccumulatedAmortization | Net |
| Finite-life intangible assets | ||||||
| Customer relationships | $151,094 | $(43,709) | $107,385 | $109,107 | $(38,377) | $70,730 |
| Trademarks and trade names | $13,570 | $(5,688) | $7,882 | $6,370 | $(5,267) | $1,103 |
| Other finite-life intangible assets | 4,171 | (3,937) | 234 | 3,904 | (3,904) | — |
| Total finite-life intangible assets | 168,835 | (53,334) | 115,501 | 119,381 | (47,548) | 71,833 |
| Indefinite-life intangible assets | 1,227 | — | 1,227 | 1,227 | — | 1,227 |
| Total intangible assets | $170,062 | $(53,334) | $116,728 | $120,608 | $(47,548) | $73,060 |
Note 8 –Debt
Debt at December 31, 2023 and April 2, 2023 consisted of the following:
| December 31,2023 | April 2,2023 | |
|---|---|---|
| (In thousands) | ||
| Senior secured revolving loan | $120,000 | $112,000 |
| Less: unamortized debt issuance costs | (290) | (356) |
| Total debt, net of debt issuance costs | 119,710 | 111,644 |
| Less: current portion of long-term debt | (9,913) | (9,913) |
| Total long-term debt | $109,797 | $101,731 |
We were in compliance with all covenants of our credit agreement as of December 31, 2023.
Note 9 –Income Taxes
We are subject to U.S. federal income tax as well as income tax of multiple state jurisdictions. The tax years prior to our fiscal year ended March 28, 2021 are closed to examination by the Internal Revenue Service, and with few exceptions, state and local income tax jurisdictions. Our effective income tax rate was 25% for the nine months ended December 31, 2023, compared to 26% for the nine months ended January 1, 2023. The effective tax rate is impacted by projected levels of annual taxable income, permanent items, and state taxes.
Note 10 –Share-Based Compensation
Performance-Based Restricted Stock Units. Our Board of Directors (the “Board”) approved a performance-based equity compensation arrangement for our executive officers during the first quarters of each of fiscal 2024 and fiscal 2023. These performance-based arrangements provide for the grant of performance-based restricted stock units that represent a possible future issuance of restricted shares of our common stock based on a pre-tax income target for the applicable fiscal year. The actual number of restricted shares to be issued to each executive officer is determined when our final financial information becomes available after the applicable fiscal year and will be between zero shares and 70,859 shares in the aggregate for fiscal 2024. The restricted shares issued, if any, will fully vest approximately two years after the last day of the fiscal year on which the performance is based. We are recording the compensation expense for the outstanding performance share units and the converted restricted stock over the life of the awards.
The following table represents the restricted stock activity for the nine months ended December 31, 2023:
| Shares | Weighted-Average GrantDate Fair Value | |
|---|---|---|
| Unvested at beginning of period | 189,258 | $34.64 |
| Granted | 61,819 | 43.06 |
| Vested | (105,600) | 31.74 |
| Unvested at end of period | 145,477 | $40.33 |
We recorded compensation expense related to performance share units and restricted stock of $1.0 million and $2.7 million for the three and nine months ended December 31, 2023, respectively. We recorded compensation expense related to performance share units and restricted stock of $0.8 million and $2.0 million for the three and nine months ended January 1, 2023, respectively. Substantially all of the compensation expense was recorded in selling, general and administrative expenses in the condensed consolidated statements of income.
Restricted Stock Awards. As part of their retainer, our directors, other than the Chief Executive Officer, receive restricted stock for their Board services. The restricted stock awards are generally expensed over a one-year vesting period, based on the market value on the date of grant. As of December 31, 2023, there were 10,647 shares of restricted stock with an average grant date fair value of $46.00 outstanding under this program. Compensation expense for both the three months ended December 31, 2023 and January 1, 2023 related to restricted stock awards to the Board was $0.1 million. Compensation expense related to restricted stock awards to the Board for the nine months ended December 31, 2023 was $0.4 million and for the nine months ended January 1, 2023 was $0.3 million.
Note 11 –Share Repurchase Program
Our Board has authorized the repurchase of up to 2.6 million shares of our outstanding common shares. The shares may be repurchased on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. Upon purchase of the shares, we reduce our common stock for the par value of the shares with the excess applied against additional paid-in capital. During the three months ended December 31, 2023, we repurchased 24,065 shares at an aggregate purchase price of $1.5 million. During the nine months ended December 31, 2023, we repurchased 191,861 shares at an aggregate purchase price of $11.3 million. During the three months ended January 1, 2023, no shares were repurchased, and during the nine months ended January 1, 2023, we repurchased 181,657 shares at an aggregate purchase price of $6.6 million. As of December 31, 2023,937,487 shares remained available to be repurchased under the share repurchase program.
Note 12 –Segment Information
We have three reportable segments: Industrial, Water Treatment, and Health and Nutrition. The accounting policies of the segments are the same as those described in the summary of significant accounting policies in our Annual Report on Form 10-K for the fiscal year ended April 2, 2023.
We evaluate performance based on profit or loss from operations before income taxes not including nonrecurring gains and losses. Reportable segments are defined primarily by product and type of customer. Segments are responsible for the sales, marketing and development of their products and services. We allocate certain corporate expenses to our operating segments. There areno intersegment sales andno operating segments have been aggregated. No single customer’s revenues amounted to 10% or more of our total revenue. Sales are primarily within the United States and all assets are located within the United States.
| (In thousands) | Industrial | WaterTreatment | Health and Nutrition | Total |
|---|---|---|---|---|
| Three months ended December 31, 2023: | ||||
| Sales | $92,990 | $82,019 | $33,487 | $208,496 |
| Gross profit | 16,495 | 20,241 | 5,512 | 42,248 |
| Selling, general, and administrative expenses | 7,292 | 12,470 | 4,012 | 23,774 |
| Operating income | 9,203 | 7,771 | 1,500 | 18,474 |
| Three months ended January 1, 2023: | ||||
| Sales | $114,436 | $68,549 | $36,233 | $219,218 |
| Gross profit | 15,994 | 13,268 | 7,009 | 36,271 |
| Selling, general, and administrative expenses | 7,978 | 9,003 | 4,023 | 21,004 |
| Operating income | 8,016 | 4,265 | 2,986 | 15,267 |
| Nine months ended December 31, 2023: | ||||
| Sales | $312,398 | $276,595 | $107,149 | $696,142 |
| Gross profit | 53,645 | 75,957 | 18,523 | 148,125 |
| Selling, general and administrative expenses | 20,673 | 31,741 | 11,759 | 64,173 |
| Operating income | 32,972 | 44,216 | 6,764 | 83,952 |
| Nine months ended January 1, 2023: | ||||
| Sales | $353,085 | $233,527 | $120,341 | $706,953 |
| Gross profit | 53,716 | 52,725 | 22,953 | 129,394 |
| Selling, general and administrative expenses | 21,254 | 26,786 | 11,687 | 59,727 |
| Operating income | 32,462 | 25,939 | 11,266 | 69,667 |
No significant changes to identifiable assets by segment occurred during the nine months ended December 31, 2023.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.